Requirement of oestrogens for the sensitivity of prolactin cells to vasoactive intestinal peptide in rats and man

M. Pizzi, S. Rubessa, E. Simonazzi, V. Zanagnolo, L. Falsetti, M. Memo, P. F. Spano

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Vasoactive intestinal peptide (VIP) is a prolactin-releasing hormone which is involved in the multifactorial modulation of prolactin secretion in mammals. Intravenous injection of VIP (1 μg/kg) to fertile women increased plasma prolactin levels and heart rate and reduced diastolic pressure. The same treatment to menopausal women caused similar cardiovascular effects but did not modify prolactin levels. In contrast, TRH (200 μg, i.v.) induced a significant increase in plasma prolactin levels in both fertile and menopausal women. The relevance of oestrogens in affecting VIP-stimulated prolactin secretion was evaluated in vitro by measuring prolactin release from pituitary cells of control and ovariectomized rats. The sensitivity of rat mammotrophs to VIP, but not to TRH, was completely suppressed 3 or 4 weeks after ovariectomy. Furthermore, implantation of rats with a silastic capsule containing oestradiol-17β during ovariectomy, preserved the cell responsiveness to VIP. The prolactin-releasing property of VIP was also restored when pituitary cells from ovariectomized rats were cultured for 3 days in the presence of 10 nmol oestradiol-17β/l before being used for prolactin release experiments. The present study shows that the ability of prolactin-secreting cells to respond to the stimulatory action of VIP requires high levels of circulating oestrogens, both in man and rats.

Original languageEnglish
Pages (from-to)311-316
Number of pages6
JournalJournal of Endocrinology
Volume132
Issue number2
Publication statusPublished - 1992

Fingerprint

Vasoactive Intestinal Peptide
Prolactin
Estrogens
Ovariectomy
Estradiol
Prolactin-Releasing Hormone
Lactotrophs
Intravenous Injections
Capsules
Mammals
Heart Rate
Blood Pressure

ASJC Scopus subject areas

  • Endocrinology

Cite this

Pizzi, M., Rubessa, S., Simonazzi, E., Zanagnolo, V., Falsetti, L., Memo, M., & Spano, P. F. (1992). Requirement of oestrogens for the sensitivity of prolactin cells to vasoactive intestinal peptide in rats and man. Journal of Endocrinology, 132(2), 311-316.

Requirement of oestrogens for the sensitivity of prolactin cells to vasoactive intestinal peptide in rats and man. / Pizzi, M.; Rubessa, S.; Simonazzi, E.; Zanagnolo, V.; Falsetti, L.; Memo, M.; Spano, P. F.

In: Journal of Endocrinology, Vol. 132, No. 2, 1992, p. 311-316.

Research output: Contribution to journalArticle

Pizzi, M, Rubessa, S, Simonazzi, E, Zanagnolo, V, Falsetti, L, Memo, M & Spano, PF 1992, 'Requirement of oestrogens for the sensitivity of prolactin cells to vasoactive intestinal peptide in rats and man', Journal of Endocrinology, vol. 132, no. 2, pp. 311-316.
Pizzi, M. ; Rubessa, S. ; Simonazzi, E. ; Zanagnolo, V. ; Falsetti, L. ; Memo, M. ; Spano, P. F. / Requirement of oestrogens for the sensitivity of prolactin cells to vasoactive intestinal peptide in rats and man. In: Journal of Endocrinology. 1992 ; Vol. 132, No. 2. pp. 311-316.
@article{c7ac96f58403411f84bdc1cb325aad74,
title = "Requirement of oestrogens for the sensitivity of prolactin cells to vasoactive intestinal peptide in rats and man",
abstract = "Vasoactive intestinal peptide (VIP) is a prolactin-releasing hormone which is involved in the multifactorial modulation of prolactin secretion in mammals. Intravenous injection of VIP (1 μg/kg) to fertile women increased plasma prolactin levels and heart rate and reduced diastolic pressure. The same treatment to menopausal women caused similar cardiovascular effects but did not modify prolactin levels. In contrast, TRH (200 μg, i.v.) induced a significant increase in plasma prolactin levels in both fertile and menopausal women. The relevance of oestrogens in affecting VIP-stimulated prolactin secretion was evaluated in vitro by measuring prolactin release from pituitary cells of control and ovariectomized rats. The sensitivity of rat mammotrophs to VIP, but not to TRH, was completely suppressed 3 or 4 weeks after ovariectomy. Furthermore, implantation of rats with a silastic capsule containing oestradiol-17β during ovariectomy, preserved the cell responsiveness to VIP. The prolactin-releasing property of VIP was also restored when pituitary cells from ovariectomized rats were cultured for 3 days in the presence of 10 nmol oestradiol-17β/l before being used for prolactin release experiments. The present study shows that the ability of prolactin-secreting cells to respond to the stimulatory action of VIP requires high levels of circulating oestrogens, both in man and rats.",
author = "M. Pizzi and S. Rubessa and E. Simonazzi and V. Zanagnolo and L. Falsetti and M. Memo and Spano, {P. F.}",
year = "1992",
language = "English",
volume = "132",
pages = "311--316",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "BioScientifica Ltd.",
number = "2",

}

TY - JOUR

T1 - Requirement of oestrogens for the sensitivity of prolactin cells to vasoactive intestinal peptide in rats and man

AU - Pizzi, M.

AU - Rubessa, S.

AU - Simonazzi, E.

AU - Zanagnolo, V.

AU - Falsetti, L.

AU - Memo, M.

AU - Spano, P. F.

PY - 1992

Y1 - 1992

N2 - Vasoactive intestinal peptide (VIP) is a prolactin-releasing hormone which is involved in the multifactorial modulation of prolactin secretion in mammals. Intravenous injection of VIP (1 μg/kg) to fertile women increased plasma prolactin levels and heart rate and reduced diastolic pressure. The same treatment to menopausal women caused similar cardiovascular effects but did not modify prolactin levels. In contrast, TRH (200 μg, i.v.) induced a significant increase in plasma prolactin levels in both fertile and menopausal women. The relevance of oestrogens in affecting VIP-stimulated prolactin secretion was evaluated in vitro by measuring prolactin release from pituitary cells of control and ovariectomized rats. The sensitivity of rat mammotrophs to VIP, but not to TRH, was completely suppressed 3 or 4 weeks after ovariectomy. Furthermore, implantation of rats with a silastic capsule containing oestradiol-17β during ovariectomy, preserved the cell responsiveness to VIP. The prolactin-releasing property of VIP was also restored when pituitary cells from ovariectomized rats were cultured for 3 days in the presence of 10 nmol oestradiol-17β/l before being used for prolactin release experiments. The present study shows that the ability of prolactin-secreting cells to respond to the stimulatory action of VIP requires high levels of circulating oestrogens, both in man and rats.

AB - Vasoactive intestinal peptide (VIP) is a prolactin-releasing hormone which is involved in the multifactorial modulation of prolactin secretion in mammals. Intravenous injection of VIP (1 μg/kg) to fertile women increased plasma prolactin levels and heart rate and reduced diastolic pressure. The same treatment to menopausal women caused similar cardiovascular effects but did not modify prolactin levels. In contrast, TRH (200 μg, i.v.) induced a significant increase in plasma prolactin levels in both fertile and menopausal women. The relevance of oestrogens in affecting VIP-stimulated prolactin secretion was evaluated in vitro by measuring prolactin release from pituitary cells of control and ovariectomized rats. The sensitivity of rat mammotrophs to VIP, but not to TRH, was completely suppressed 3 or 4 weeks after ovariectomy. Furthermore, implantation of rats with a silastic capsule containing oestradiol-17β during ovariectomy, preserved the cell responsiveness to VIP. The prolactin-releasing property of VIP was also restored when pituitary cells from ovariectomized rats were cultured for 3 days in the presence of 10 nmol oestradiol-17β/l before being used for prolactin release experiments. The present study shows that the ability of prolactin-secreting cells to respond to the stimulatory action of VIP requires high levels of circulating oestrogens, both in man and rats.

UR - http://www.scopus.com/inward/record.url?scp=0026557272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026557272&partnerID=8YFLogxK

M3 - Article

VL - 132

SP - 311

EP - 316

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 2

ER -